BAMCO INC /NY/ - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.

Quarter-by-quarter ownership
BAMCO INC /NY/ ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,041,815
-30.1%
50,5000.0%0.00%
-25.0%
Q2 2023$1,490,255
+28.1%
50,5000.0%0.00%
+33.3%
Q1 2023$1,163,520
-84.2%
50,500
-80.9%
0.00%
-88.0%
Q4 2022$7,348,959
-12.9%
264,256
-3.9%
0.02%
-7.4%
Q3 2022$8,436,000
+4.0%
274,862
-0.3%
0.03%
+3.8%
Q2 2022$8,114,000
-61.5%
275,705
-57.9%
0.03%
-50.0%
Q1 2022$21,083,000
-52.6%
655,348
-34.2%
0.05%
-44.7%
Q4 2021$44,435,000
-21.9%
996,304
-11.7%
0.09%
-27.1%
Q3 2021$56,904,000
-42.2%
1,127,919
-10.1%
0.13%
-42.7%
Q2 2021$98,460,000
+42.5%
1,255,224
+3.8%
0.22%
+32.4%
Q1 2021$69,081,000
-22.4%
1,209,824
+13.8%
0.17%
-22.7%
Q4 2020$89,071,000
+159.4%
1,063,406
+11.0%
0.22%
+109.5%
Q3 2020$34,333,000
+49.0%
958,206
+0.6%
0.10%
+26.5%
Q2 2020$23,043,000
+38.1%
952,9570.0%0.08%
+1.2%
Q1 2020$16,686,000
+0.5%
952,9570.0%0.08%
+30.2%
Q4 2019$16,601,000
+10.0%
952,957
-3.2%
0.06%
+1.6%
Q3 2019$15,085,000
-26.2%
984,6620.0%0.06%
-24.4%
Q2 2019$20,442,000
-10.6%
984,6620.0%0.08%
-15.5%
Q1 2019$22,864,000
+12.5%
984,662
+0.1%
0.10%
-5.8%
Q4 2018$20,327,000
-2.1%
983,902
+3.0%
0.10%
+19.8%
Q3 2018$20,770,000
+44.1%
955,402
+1.1%
0.09%
+36.5%
Q2 2018$14,418,000
-19.8%
945,462
+3.5%
0.06%
-24.1%
Q1 2018$17,987,000
+134.7%
913,525
+86.4%
0.08%
+137.1%
Q4 2017$7,664,000490,0000.04%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Crestline Management, LP 7,705,039$343,645,00025.68%
Casdin Capital, LLC 1,500,000$66,900,0001.89%
Flagship Pioneering Inc. 2,619,968$116,851,0001.81%
SECTORAL ASSET MANAGEMENT INC 189,600$8,456,0001.27%
Integral Health Asset Management, LLC 100,000$4,460,0001.23%
Temasek Holdings (Private) Ltd 5,369,487$239,479,0000.86%
Goldstream Capital Management Ltd 78,418$3,497,0000.86%
Yiheng Capital Management, L.P. 335,184$14,949,0000.76%
GILDER GAGNON HOWE & CO LLC 2,900,114$129,345,0000.74%
Artal Group S.A. 600,000$26,760,0000.73%
View complete list of DENALI THERAPEUTICS INC shareholders